LEADER 03483nam 2200625 a 450 001 9910967542303321 005 20251116181638.0 010 $a1-61761-457-2 035 $a(CKB)2550000001042096 035 $a(EBL)3019248 035 $a(SSID)ssj0000854109 035 $a(PQKBManifestationID)12308034 035 $a(PQKBTitleCode)TC0000854109 035 $a(PQKBWorkID)10902974 035 $a(PQKB)10486015 035 $a(MiAaPQ)EBC3019248 035 $a(Au-PeEL)EBL3019248 035 $a(CaPaEBR)ebr10670813 035 $a(OCoLC)830627853 035 $a(BIP)28103808 035 $a(EXLCZ)992550000001042096 100 $a20091020d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance /$fSang Geon Kim, Il Je Cho and Hee Yeon Kay 205 $a1st ed. 210 $aNew York $cNova Science Publishers$dc2010 215 $a1 online resource (69 p.) 225 1 $aHepatology research and clinical developments series 300 $aDescription based upon print version of record. 311 08$a1-60876-693-4 320 $aIncludes bibliographical references (p. [33]-49) and index. 327 $aIntroduction: Insulin signaling in hepatocytes -- Clinical and preclinical drugs for the treatment of hepatic insulin resistance. 330 $aHepatic insulin resistance and altered insulin metabolism, as characterized by the desensitization of hepatic parenchymal cells to insulin, play a role in the pathogenesis of liver disease, particularly resulting in steatosis and steatohepatitis. By the same token, type II diabetic patients are at higher risk for developing liver diseases, including steatosis, hepatitis, cirrhosis, and hepatocellular carcinoma. On the other hand, established liver disease from any cause leads to glucose intolerance and peripheral insulin resistance systemically. The link between insulin resistance and liver pathology reviewed in this book suggests that insulin resistance is closely related with a variety of liver diseases. Recent evidence indicates that the AMP activating protein kinase (AMPK) in conjunction with p70 ribosomal S6 kinase 1 (S6K1) serves as a key signaling pathway regulating insulin-dependent physiological functions; thus, this pathway serves as a target for the therapy of diseases associated with insulin resistance. In this chapter, the regulatory role of the AMPK-S6K1 pathway is discussed in terms of enhancing insulin receptor signaling with insulin receptor substrate-1/2 and phosphatidylinositol phosphate kinase activity, which may contribute to preventing and/or treating insulin resistance in the liver. 410 0$aHepatology research and clinical developments series. 606 $aInsulin resistance$xMolecular aspecsts 606 $aLiver$xDiseases$xMolecular aspecsts 606 $aProtein kinases 615 0$aInsulin resistance$xMolecular aspecsts. 615 0$aLiver$xDiseases$xMolecular aspecsts. 615 0$aProtein kinases. 676 $a616.3/6207 700 $aKim$b Sang Geon$01860971 701 $aCho$b Il Je$01860972 701 $aKay$b Hee Yeon$01860973 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910967542303321 996 $aAMPK-S6K1 signaling pathway as a target for treating hepatic insulin resistance$94466980 997 $aUNINA